Bellier Alexandre, Colonna Marc, Delafosse Patricia, Seigneurin Arnaud
Registre du Cancer de l'Isère, Grenoble, BP 217, 38043 Grenoble Cedex 09, France.
Registre du Cancer de l'Isère, Grenoble, BP 217, 38043 Grenoble Cedex 09, France; Centre Hospitalier Universitaire Grenoble Alpes, Pôle Santé Publique, Service d'évaluation médicale, BP 217, 38043 Grenoble Cedex 09, France; Université Grenoble Alpes, Laboratoire Techniques de l'Ingénierie Médicale et de la Complexité - Informatique Mathématiques et Applications, Grenoble, France.
Cancer Epidemiol. 2018 Oct;56:60-66. doi: 10.1016/j.canep.2018.07.007. Epub 2018 Jul 23.
Prostate cancer is the leading type of cancer among men in more developed countries. Incidence trends and survival rates could differ by age groups considering potential differences in the frequency of PSA testing, types of cancers and medical management. Our objective was to compare incidence trends and survival rates of prostate cancer between men aged ≥75 and 60-74 years.
We analyzed data from a population-based cancer registry in Isère, France. All men aged ≥60 years diagnosed with an incident prostate cancer during the 1991-2013 period were included. Incidence and mortality rates were computed as well as net survival rates.
In 2013, observed incidence rates were 557.6 and 568.7 per 100,000 for men aged 60-74 and ≥75, respectively, with high grades cancers more frequent among elderly men. The incidence and mortality trends among men aged ≥75 included a period of stability followed by a decreasing trend from 2003, whereas a peak of incidence was observed in 2005 for men aged 60-74. For both age groups, net survival rates increased with period of diagnosis and 8-year net survival remained higher than 70% for cases diagnosed in the 2000-2004 period. Lower survival rate of 51% (95%CI: 42%; 60%) was observed for high grades cancers diagnosed among men aged 75-84 in 2000-2004.
The epidemiology of prostate cancers among men aged ≥75 include a decrease of incidence and mortality rates from 2003, an important proportion of high grade cancers and a relatively good prognosis except for high grade cancers.
在较发达国家，前列腺癌是男性中最主要的癌症类型。考虑到前列腺特异性抗原（PSA）检测频率、癌症类型和医疗管理方面的潜在差异，发病率趋势和生存率可能因年龄组而异。我们的目的是比较75岁及以上男性与60 - 74岁男性前列腺癌的发病率趋势和生存率。
我们分析了法国伊泽尔省基于人群的癌症登记数据。纳入了所有在1991 - 2013年期间诊断为原发性前列腺癌的60岁及以上男性。计算了发病率、死亡率以及净生存率。
2013年，60 - 74岁男性和75岁及以上男性的观察发病率分别为每10万人557.6例和568.7例，老年男性中高分级癌症更为常见。75岁及以上男性的发病率和死亡率趋势包括一段稳定期，随后从2003年开始呈下降趋势，而60 - 74岁男性在2005年观察到发病率峰值。对于这两个年龄组，净生存率随诊断时间增加，2000 - 2004年诊断的病例8年净生存率仍高于70%。2000 - 2004年在75 - 84岁男性中诊断的高分级癌症观察到较低的生存率，为51%（95%置信区间：42%；60%）。
75岁及以上男性前列腺癌的流行病学特征包括自2003年起发病率和死亡率下降、高分级癌症占重要比例以及除高分级癌症外相对较好的预后。
